Note: The COVID-19 situation is continuously evolving; health care professionals can subscribe hereto receive updates.
Click here to see the most recent Public Health Alerts for health care professionals
Clinical Resources
HCP COVID-19 Vaccine pre-filled syringe for pick up requests
COVID-19 Third Dose Referral Form - NEW
COVID-19 Vaccine Third Dose Recommendations - NEW
The 4A Model - Minimal Contact COVID-19 Vaccine Intervention
Patients with a severe allergy to a component of mRNA vaccine (i.e. PEG) A primary care referral to an allergist is required when there is an allergy concern related to an mRNA COVID-19 vaccine. The allergist will prescribe and administer the appropriate vaccine. Allergists - please call us at 705-721-7520 ext. 8806 to request a dose of Astra Zeneca vaccine for these clients.
Getting Ready for your COVID-19 Vaccine
COVID-19 Vaccine Consent Form
COVID-19 Fact Sheet
Moderna COVID-19 Vaccine Directive Template (Revised September 29, 2021)
Pfizer COVID-19 Vaccine Directive Template (Revised September 29, 2021)
Astra Zeneca COVID-19 Directive Template (Revised September 29, 2021)
COVID-19 Vaccination: Special Populations (Ministry of Health)- Vaccination in Pregnancy & Breastfeeding Decision-Making Support Tool (April 15,2021)
Pregnancy and Breastfeeding Decision-Making Tool (March 8, 2021) Provincial Council for Maternal Child Health
Guidance for Obstetrics and Perinatal Care (Society of Obstetricians and Gynaecologists of Canada)
COVID-19 Vaccine - Relevant Information and Planning Resources
Primary care providers can now access both Pfizer BioNTech COVID-19 vaccine or Moderna COVID-19 vaccine through public health to administer in their practice. Both of these vaccines are mRNA vaccines with similar efficacy and safety profiles. While they are stored until use in the frozen state and are sensitive to movement, they can be moved one time in the thawed state with appropriate precautions (from PHU office to Primary care practice) and then stored in the facility’s regular vaccine fridge as per the table below:
Pfizer BioNTech Vaccine
Moderna Vaccine
12 years and older
18 years and older
Dose = 0.3 mL
Dose = 0.5 mL
6 dose vial – must be reconstituted with provided diluent
14 dose vial – no reconstitution required
Unpunctured vials stable in fridge for up to 31 days
Unpunctured vials stable in fridge for up to 30 days
Once reconstituted the vial is stable for 6 hours
Once punctured the vial is stable for 24 hours
The following steps are required to provide COVID-19 vaccine and public health is here to support you in onboarding with this process:
Clinical supplies (needles, alcohol swabs, cotton, PPE, sharps containers) will be provided with each vaccine order.
If you are interested in accessing COVID-19 vaccine (Astra Zeneca, Pfizer, Moderna) to store, handle and administer in your practice, please email [email protected] indicating your interest and someone will connect with you to review next steps.
Link to Pfizer Vaccine Reconstitution and Prep
Other Web Links:
COVID-19 Vaccine Information - Public Health Agency of Canada
COVID-19 Vaccines for Ontario - Ontario Ministry of Health
Pfizer-BioNTech COVID-19 Vaccine 9 (tozinameran) Product Monograph
Moderna COVID-19 Vaccine Product Monograph
NACI Recommendations on the use of COVID-19 vaccine(s)
NACI Guidance on the prioritization of initial doses of COVID-19 vaccine(s)
Novel coronavirus can cause illness ranging from a very mild, cold-like illness to a severe lung infection. Some common symptoms are:
Some people such as the elderly and those who are immunocompromised may not develop a fever. For these individuals, the presence of new/worse cough or difficulty breathing may be enough to trigger further precautions.
Complications from the 2019 novel coronavirus can include serious conditions, like pneumonia or kidney failure, and in some cases, death.
SMDHU COVID-19 Variant of Concern (VOC) Strategy
Assessment of Exposure Risk: COVID-19 Variants of Concern
Ministry of Health-COVID-19 Variant of Concern: Case, Contact and Outbreak Management Interim Guidance
Variant of Concern (VOC) Surveillance Testing
Newest Guidelines/Documents
Accessing Personal Protective Equipment (PPE): If unable to access PPE through the usual suppliers see the Ontario Health: Quick Reference - PPE and Critical Supplies Escalation Process for assistance in requesting from the provincial supply.
Increased frequency of cleaning high-touch surfaces is significant in controlling the spread of microorganisms during a respiratory infection outbreak. Environmental cleaning products registered in Canada with a Drug Identification Number (DIN) and labelled as a broad-spectrum virucide are sufficient for 2019-nCoV. All surfaces, especially those that are horizontal and frequently touched, should be cleaned at least twice daily and when soiled. The healthcare organization's terminal cleaning protocol for cleaning of the patient's room after discharge, transfer, or discontinuation of contact and droplet precautions should be followed.
Public Settings
Case Management
Reporting
Testing
Specimen Collection Information
Other Links
